JP2024540319A - 肺粘膜炎症の処置のための低分子量ヒアルロン酸の使用 - Google Patents

肺粘膜炎症の処置のための低分子量ヒアルロン酸の使用 Download PDF

Info

Publication number
JP2024540319A
JP2024540319A JP2024526661A JP2024526661A JP2024540319A JP 2024540319 A JP2024540319 A JP 2024540319A JP 2024526661 A JP2024526661 A JP 2024526661A JP 2024526661 A JP2024526661 A JP 2024526661A JP 2024540319 A JP2024540319 A JP 2024540319A
Authority
JP
Japan
Prior art keywords
kda
f508del
hyaluronic acid
treatment
decrease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526661A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540319A5 (cg-RX-API-DMAC10.html
Inventor
コロー，クリステル
ルチカ，エミリー
ポーレット，ミリアム
アダム，ダミアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agro Industrie Recherches Et Developpements(ard)
Centre Hospitalier Universitaire de Reims
Original Assignee
Agro Industrie Recherches Et Developpements(ard)
Centre Hospitalier Universitaire de Reims
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agro Industrie Recherches Et Developpements(ard), Centre Hospitalier Universitaire de Reims filed Critical Agro Industrie Recherches Et Developpements(ard)
Publication of JP2024540319A publication Critical patent/JP2024540319A/ja
Publication of JP2024540319A5 publication Critical patent/JP2024540319A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024526661A 2021-11-05 2022-11-04 肺粘膜炎症の処置のための低分子量ヒアルロン酸の使用 Pending JP2024540319A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306554.3 2021-11-05
EP21306554 2021-11-05
PCT/EP2022/080807 WO2023079072A1 (en) 2021-11-05 2022-11-04 Use of low molecular weight hyaluronic acid for the treatment of lung mucosal inflammation

Publications (2)

Publication Number Publication Date
JP2024540319A true JP2024540319A (ja) 2024-10-31
JP2024540319A5 JP2024540319A5 (cg-RX-API-DMAC10.html) 2025-09-16

Family

ID=78770564

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526661A Pending JP2024540319A (ja) 2021-11-05 2022-11-04 肺粘膜炎症の処置のための低分子量ヒアルロン酸の使用

Country Status (4)

Country Link
US (1) US20260158056A1 (cg-RX-API-DMAC10.html)
EP (1) EP4426317A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024540319A (cg-RX-API-DMAC10.html)
WO (1) WO2023079072A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026502695A (ja) * 2023-01-26 2026-01-23 インシグニア・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー 変形性関節症の処置のための医薬組成物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050187A1 (fr) * 2002-11-28 2004-06-17 Agro Industrie Recherches Et Developpements (A.R.D.) Utilisation d'acide hyaluronique pour les affections respiratoires des voies aeriennes superieures.
US7060691B2 (en) * 2002-10-10 2006-06-13 Giuseppe Petrigni Pharmaceutical colloidal preparation useful in the treatment of respiratory diseases
WO2009024677A2 (fr) * 2007-07-23 2009-02-26 Agro Industrie Recherches Et Developpements A.R.D. Utilisation d'acide hyaluronique pour la preparation de compositions destinees a l'amelioration notamment de la fonction de protection de la peau, de l'oeil et des muqueuses
CN105018547A (zh) * 2014-04-16 2015-11-04 惠觅宙 一种生物活性透明质酸片段、其生产方法、应用、制剂及含有该制剂的物品
CN111632042A (zh) * 2020-06-15 2020-09-08 华熙生物科技股份有限公司 透明质酸吸入剂及其制备方法和应用
WO2021222385A1 (en) * 2020-04-29 2021-11-04 Avm Biotechnology, Llc Glucocorticoid receptor (gr) modulators for treating a sars-cov-2 virus
WO2022236585A1 (zh) * 2021-05-10 2022-11-17 傅毓秀 玻尿酸用于制备治疗肺纤维化药剂的用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060691B2 (en) * 2002-10-10 2006-06-13 Giuseppe Petrigni Pharmaceutical colloidal preparation useful in the treatment of respiratory diseases
WO2004050187A1 (fr) * 2002-11-28 2004-06-17 Agro Industrie Recherches Et Developpements (A.R.D.) Utilisation d'acide hyaluronique pour les affections respiratoires des voies aeriennes superieures.
WO2009024677A2 (fr) * 2007-07-23 2009-02-26 Agro Industrie Recherches Et Developpements A.R.D. Utilisation d'acide hyaluronique pour la preparation de compositions destinees a l'amelioration notamment de la fonction de protection de la peau, de l'oeil et des muqueuses
CN105018547A (zh) * 2014-04-16 2015-11-04 惠觅宙 一种生物活性透明质酸片段、其生产方法、应用、制剂及含有该制剂的物品
WO2021222385A1 (en) * 2020-04-29 2021-11-04 Avm Biotechnology, Llc Glucocorticoid receptor (gr) modulators for treating a sars-cov-2 virus
CN111632042A (zh) * 2020-06-15 2020-09-08 华熙生物科技股份有限公司 透明质酸吸入剂及其制备方法和应用
WO2022236585A1 (zh) * 2021-05-10 2022-11-17 傅毓秀 玻尿酸用于制备治疗肺纤维化药剂的用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Use of Inhaled High-molecular Weight Hyaluronan in Patients With Severe COVID19:Feasibility and Outc", CLINICALTRIAL.GOV, JPN6026016904, 31 March 2021 (2021-03-31), ISSN: 0005856727 *
MATRIX BIOLOGY, vol. 30, JPN6026016905, 2011, pages 389 - 395, ISSN: 0005856726 *
PEDIATRIC DRUGS, vol. Vol. 11, Issue 2, JPN6026016903, 2009, pages 101 - 113, ISSN: 0005856728 *
PEDIATRIC PULMONOLOGY, vol. 48, JPN6026016906, 2013, pages 761 - 771, ISSN: 0005856725 *
RESPIRATORY MEDICINE, vol. 99, JPN6026016902, 2005, pages 1494 - 1500, ISSN: 0005856729 *

Also Published As

Publication number Publication date
US20260158056A1 (en) 2026-06-11
EP4426317A1 (en) 2024-09-11
WO2023079072A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
JP5247265B2 (ja) 気道流路および肺疾患の処置のためのモメタゾンフロエートの使用
US6677323B2 (en) Use of mometasone furoate for treating airway passage and lung diseases
CN102448496B (zh) 含碘和类固醇的药物组合物及其用于治疗鼻炎疾病的用途
MX2008010173A (es) Antitripsina alfa-i para tratar episodios de exacerbacion de enfermedades pulmonares.
EP2923702A1 (en) Composition of cyclodextrin with budesonide derivatives for treatment and prevention of pulmonary inflammatory disease
US20090022671A1 (en) Treatment methods
EP1847256B1 (en) Antibacterial compositions for the treatment of infections of the upper and lower airways
EP0756486A1 (en) Pharmaceutical inhalation compositions containing a solid active ingredient
EP4426317A1 (en) Use of low molecular weight hyaluronic acid for the treatment of lung mucosal inflammation
Szefler A review of budesonide inhalation suspension in the treatment of pediatric asthma
Gümrü et al. Oral candidiasis as a local adverse effect of inhaled corticosteroids: what the dental practitioner should know
Poli et al. Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healty male volunteers
US20040132700A1 (en) Use of fluticasone propionate in the treatment of diseases ameliorated by enhancement of epithelial madrix adhesion such as asthma cystic fibrosis and influenza
WO2023011635A1 (en) New treatment of immunodeficiency disorder
RU2614716C2 (ru) Фармацевтическая композиция для применения назальным введением, содержащая кортикостероид и хинолон или фузидовую кислоту
WO2002002126A1 (en) Medicaments containing dextrin for treating respiratory disorders such as cystic fibrosis
CN117693352A (zh) 针对气道疾病的谷胱甘肽c4
WO2002102317A2 (en) Treatment of respiratory conditions associated with bronchoconstriction with aerosolized hyaluronic acid
WO2023203306A1 (en) Compositions and applications thereof
Szefler Reply to Drs Seale and Donnelly
Groncy et al. Allergy: Beclomethasone—An Inhaled Steroid for Bronchial Asthma
WO2018069830A1 (en) Pharmaceutical composition for the treatment of sinusitis and COPD

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260512